Paper Details

  1. Home
  2. Paper Details

Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.

Author: AshidaK, ChibaT, HiramatsuN, IwakiriK, KudouK, NishimuraA, SakuraiY, UmegakiE

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A multicentre, randomised, double-blind, parallel-group, dose-ranging study of 732 patients with erosive oesophagitis (EO) found that vonoprazan (VPZ) was effective and non-inferior to lansoprazole (LPZ) in healing EO. VPZ 20 mg or higher was highly efficacious for severe EO.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The potassium-competitive acid blocker vonoprazan (VPZ) has potent acid-inhibitory effects and may offer clinical advantages over conventional therapy for acid-related disorders. AIM: To investigate the efficacy and safety of VPZ in patients with erosive oesophagitis (EO). METHODS: In ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5014135/

データ提供：米国国立医学図書館（NLM）

A New Hope for Erosive Esophagitis: Vonoprazan Takes the Stage

This research explores the potential of a novel drug, vonoprazan (VPZ), in treating erosive esophagitis (EO). Think of EO as a sore throat, but in the esophagus, the tube that carries food from your mouth to your stomach. This study, conducted in a multicenter, randomized, double-blind setting, aimed to compare the efficacy and safety of VPZ with lansoprazole (LPZ), a commonly used treatment for EO. The study found that VPZ was non-inferior to LPZ in healing EO, especially in patients with severe EO. VPZ doses of 20 mg or higher showed promising results in healing severe EO.

Vonoprazan: A Promising Alternative

The results of this study suggest that VPZ could be a valuable alternative to LPZ in the treatment of EO. The researchers also noted that VPZ was well-tolerated, with similar safety profiles across all dosage groups. The study revealed a dose-dependent increase in serum gastrin, but no safety concerns were observed within the 8-week study period. Based on these findings, the researchers recommend VPZ 20 mg once daily as the optimal clinical dose for treating EO.

Living with Erosive Esophagitis: Tips for Management

If you're struggling with EO, it's important to follow your doctor's recommendations for treatment. This may include lifestyle changes, such as avoiding spicy foods, alcohol, and caffeine, which can irritate the esophagus. Regular follow-up with your healthcare provider is essential to monitor your condition and ensure that your treatment is effective. This research offers a glimmer of hope for individuals battling EO, suggesting that VPZ could provide a safe and effective treatment option.

Dr.Camel's Conclusion

The study provides a beacon of hope for individuals suffering from erosive esophagitis. The findings highlight the potential of vonoprazan as a new therapeutic option, offering effective treatment with a favorable safety profile. This research is a testament to the ongoing efforts in the medical field to develop better and safer treatments for challenging conditions.

Date :
  1. Date Completed 2016-03-03
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

26201312

DOI: Digital Object Identifier

PMC5014135

Related Literature

Article Analysis
・Effects of vonoprazan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.